Author: Castaneda-Puglianini, Omar; Chavez, Julio C
Title: Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma Cord-id: j00vcs51 Document date: 2021_9_21
ID: j00vcs51
Snippet: Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity i
Document: Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.
Search related documents:
Co phrase search for related documents- acute kidney injury and low concentration: 1, 2, 3
- acute kidney injury and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute kidney injury and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- liver transaminase and lung infection: 1
- long distance and low concentration: 1, 2
- long term survival and low incidence: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date